1. Home
  2. BEAM vs TPC Comparison

BEAM vs TPC Comparison

Compare BEAM & TPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BEAM
  • TPC
  • Stock Information
  • Founded
  • BEAM 2017
  • TPC 1894
  • Country
  • BEAM United States
  • TPC United States
  • Employees
  • BEAM N/A
  • TPC N/A
  • Industry
  • BEAM Biotechnology: Biological Products (No Diagnostic Substances)
  • TPC General Bldg Contractors - Nonresidential Bldgs
  • Sector
  • BEAM Health Care
  • TPC Consumer Discretionary
  • Exchange
  • BEAM Nasdaq
  • TPC Nasdaq
  • Market Cap
  • BEAM 2.3B
  • TPC 2.5B
  • IPO Year
  • BEAM 2020
  • TPC N/A
  • Fundamental
  • Price
  • BEAM $23.23
  • TPC $68.27
  • Analyst Decision
  • BEAM Strong Buy
  • TPC Strong Buy
  • Analyst Count
  • BEAM 11
  • TPC 4
  • Target Price
  • BEAM $49.40
  • TPC $71.50
  • AVG Volume (30 Days)
  • BEAM 2.6M
  • TPC 550.9K
  • Earning Date
  • BEAM 11-04-2025
  • TPC 11-05-2025
  • Dividend Yield
  • BEAM N/A
  • TPC N/A
  • EPS Growth
  • BEAM N/A
  • TPC N/A
  • EPS
  • BEAM N/A
  • TPC N/A
  • Revenue
  • BEAM $55,701,000.00
  • TPC $5,103,323,000.00
  • Revenue This Year
  • BEAM N/A
  • TPC $24.11
  • Revenue Next Year
  • BEAM $19.01
  • TPC $11.90
  • P/E Ratio
  • BEAM N/A
  • TPC N/A
  • Revenue Growth
  • BEAM N/A
  • TPC 19.22
  • 52 Week Low
  • BEAM $13.53
  • TPC $18.34
  • 52 Week High
  • BEAM $35.25
  • TPC $77.00
  • Technical
  • Relative Strength Index (RSI)
  • BEAM 42.93
  • TPC 57.62
  • Support Level
  • BEAM $26.90
  • TPC $63.72
  • Resistance Level
  • BEAM $26.17
  • TPC $70.45
  • Average True Range (ATR)
  • BEAM 1.84
  • TPC 3.61
  • MACD
  • BEAM -0.68
  • TPC -0.08
  • Stochastic Oscillator
  • BEAM 11.47
  • TPC 43.50

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

About TPC Tutor Perini Corporation

Tutor Perini Corp offers general contracting, construction management, and design-build services to private and public customers. The company constructs and repairs transportation infrastructure, water-treatment facilities, and a wide range of buildings. Tutor Perini has three operating segments: Civil, Building, and Specialty Contractors. A majority of its revenue is generated from the Civil segment, which specializes in public works construction and the replacement and reconstruction of infrastructure. Its civil contracting services include construction and rehabilitation of highways, bridges, tunnels, mass-transit systems, military and other government facilities, and water management and wastewater treatment facilities. Geographically, it derives key revenue from the United States.

Share on Social Networks: